MEDTRONIC HEART VALVES DIVISION ENVEO PRO DELIVERY SYSTEM; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV
|
Back to Search Results |
|
Model Number ENVPRO-16 |
Device Problem
Patient Device Interaction Problem (4001)
|
Patient Problem
Hematoma (1884)
|
Event Date 03/18/2022 |
Event Type
Injury
|
Manufacturer Narrative
|
This report is being submitted as part of a retrospective review and remediation per d00916038.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
Medtronic received information that three days following the implant of this transcatheter bioprosthetic valve via the right femoral route/puncture site, the patient presented to the emergency room and a femoral hematoma was identified.Hospitalization was reported.Manual compression was provided in the emergency room.Hematoma of the right scarpa was identified.There was no deglobulization.Three days later, echocardiogram showed no pseudoaneurysm or arteriovenous fistula.Hemoglobin four days before the valve implant surgery was 13 g/dl.Four days following the valve implant the hemoglobin was 12.1 g/dl.Six days following the valve implant the hemoglobin was 12.5 g/dl.A blood transfusion was not required.No additional treatment was provided.As reported, the cause of hematoma not determined but it was reported that the hematoma was not caused by sheath, delivery catheter system (dcs), nor the valve.There was no anatomical prerequisite that could have contributed to this injury.The event was noted to be resolved approximately one month following onset.Additional information was received that reported the patient's discharge occurred four days after admission.
|
|
Search Alerts/Recalls
|
|
|